Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler

Similar documents
TCR, MHC and coreceptors

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU

New insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

Adaptive immune responses: T cell-mediated immunity

Defensive mechanisms include :

Adaptive (acquired) immunity. Professor Peter Delves University College London

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Tumor Microenvironment and Immune Suppression

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Synergistic combinations of targeted immunotherapy to combat cancer

chapter 17: specific/adaptable defenses of the host: the immune response

Supplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was

The Adaptive Immune Responses

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1

I * TITLE: Immunotherapeutic Strategies in Breast Cancer; Preclinical and Clinical Trials

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

Excerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴

Nobel Prize in Physiology or Medicine 2018

Immune response. This overview figure summarizes simply how our body responds to foreign molecules that enter to it.

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

Supplementary Figure 1. Example of gating strategy

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier

Focused Ultrasound and Cancer Immunotherapy

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

Understanding the T cell response to tumors using transnuclear mouse models

Tumor Associated Macrophages as a Novel Target for Cancer Therapy

Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited

Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

Lecture 4. T lymphocytes

Immunotherapy of HNC: immune mechanisms and therapeutic targets

Posters and Presentations

Immunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters,

The T cell receptor for MHC-associated peptide antigens

Radiation Therapy as an Immunomodulator

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

Immunotherapy on the Horizon: Adoptive Cell Therapy

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

T cell-mediated immunity

Cellular Immunity in Aging and HIV: Correlates of Protection. Immune Senescence

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.

Practical Solution: presentation to cytotoxic T cells. How dendritic cells present antigen. How dendritic cells present antigen

There has recently been great interest in cancer vaccines,

Tumor Immunology. Tumor (latin) = swelling

TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION

Adoptive T Cell Therapy:

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Additional file 6. Summary of experiments characterizing development of adaptive immune response

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

1. Overview of Adaptive Immunity

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia

LESSON 2: THE ADAPTIVE IMMUNITY

TITLE: Tumor Specific CD4+ T-Cell Costimulation Through a Novel Receptor/Ligand Interaction

Third line of Defense

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immunotherapy in lung cancer. Saurabh maji

T cell and Cell-mediated immunity

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas

AD (Leave blank) TITLE: Enhancement of Dendritic Cell-Based Immunotherapy Using a Small Molecule TGFbeta Receptor Type I Kinase Inhibitor

Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine

Lecture 9: T-cell Mediated Immunity

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Cancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.

Chapter 17B: Adaptive Immunity Part II

Engineering chimeric antigen receptor-t cells for cancer treatment

Texas Medical Center Library. Yan Yang

NANO 243/CENG 207 Course Use Only

The effects of host response and vaccine design on early signaling profiles of MUC1-specific T cells. Dawn Kristin Reichenbach

The development of T cells in the thymus

Transcription:

Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler

Goal of Immunotherapy Boosting the low level anti-tumor immune response Generate long lasting strong antitumor CTL and helper response Avoid tumor-induced immune suppression

MUC1 is a target for Immunotherapy

Schematic representation of a mouse model of spontaneous metastatic breast cancer and approximate time-line of tumor progression from hyperplasia to adenocarcinomas and metastasis.

Increased MUC1 expression as tumors progress

Immunotherapy (Preclinical Trials) Single tumor antigen-based vaccine Dendritic cells pulsed with liposomal-muc1 peptide (JI 2000, JIT 2003, and Glycoconjugate J. 2003) Tumor based vaccine Dendritic cells fused with primary resectable tumor cells (JI 2003, Immunol 2004, and JS 2002) Dendritic cells fed with whole tumor cell lysate + costimulatory factors (41BB, OX40, CD40 antibody) Cytotoxic T cell adoptive therapy

MUC1-specific Cytotoxic T lymphocytes isolated from a pancreatic cancer model MET mice naturally develop MUC1-specific CTLs as the pancreas tumor progresses Several clones of MUC1-specific CTLs were isolated from these MET mice and characterized

Epitopes recognized by MUC1-specific CTL line and clone.

CTL clone expresses high levels of perforin and granzyme B Perforin and Granzyme A and B are components of the cytolytic granule of cytotoxic T cells and NK cells that mediates lymphocyte-dependent killing

Adoptive transfer of MUC1-specific CTLs eradicates injected tumors that express MUC1 and generates a strong memory response

Adoptively transferred MUC1-specific CTL clone inhibits tumor progression in MMT mice.

Immunosuppressive factor (TGF-β) is expressed and secreted in the tumor microenvironment A.Growth inhibition of MvlLu cells that are sensitive to TGF-β inhibition B. Inhibition of CTL cytolytic function Bioactive form of TGFβ is secreted by MET tumor cells in culture. Supernatant derived from MET tumor cells inhibits cytolytic activity of the CTL clone.

Immunosuppressive Factor (IL-10) is secreted in the tumor microenvironment

COX-2 and PGE 2 is present in the mammary tumor microenvironment

Adoptively transferred CTLs home and divide within the tumor microenvironment

CD137 Member of the tumor necrosis factor receptor superfamily expressed on primed but not on naïve CD4 + and CD8 + T cells Binds to a high affinity ligand expressed on APCs and delivers a mitogenic signal for T cell activation and proliferation CD137 monoclonal antibodies can amplify T cell-mediated immune responses and can eradicate established tumors Postulated to reverse T cell tolerance induced by tumor cells Tested efficacy of CD137 antibody therapy in reversing tolerance in the in vivo breast cancer model

Flow cytometric profile of TCR Vβ5 + /CD8 + T cells sorted from TILs by flow cytometry TILs were isolated from tumors of MMT mice that received adoptively transferred MUC1-specific CTL clone

Adoptively transferred CTL become tolerant to MUC1 antigen within the tumor microenvironment

Adoptively transferred CTL are cytolytically inactive within the tumor microenvironment.

Adoptively transferred CTL are negative for granzyme expression within the tumor microenvironment.

Anti 4-1BB in combination with MUC1-specific CTL therapy is more efficient in reducing tumor burden than CTL therapy alone CTL injection Anti-CD137 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 sacrificed

Conclusions Inefficiency of MUC1 CTLs to affect tumor burden and survival in spontaneous tumor models is due to the immunosuppressive tumor microenvironment that renders the infiltrating CTLs inactive Adoptively transferred CTL become tolerant to MUC1 and are cytolytically inactive after encounter with tumor cells. Anti-CD137 antibody can reverse tolerance in MMT mice and has synergistic anti-tumor affect when combined with MUC1-specific CTL therapy.

Acknowledgements Teresa Tinder Latha Pathangey Dr. Gargi Basu Dr. Sandra Gendler Dr. Leiping Chen Carol Williams Marvin Ruona (Visual Communication) Histology Core in Scottsdale Jim Tarara (Flow Cytometry) Animal Facility in Scottsdale